LONDON, Sept. 17, 2002 (PRIMEZONE) -- Interview available now on www.cantos.com with David P Southwell, Executive Vice-President/Chief Financial Officer.
Issues around the non approvable letter received issued by the FDA on the potential blockbuster drug Soltara; the logic behind the co-promotion deal of Medipointe's Astelin and the strength of the Sepracor (Nasdaq:SEPR) pipeline over an 18 month view.
Interviews with Affymetrix, Genzyme General and Vertex also available on Cantos today.
This interview is available in video, audio and transcript.
It's free to view. All you need to do is register at http://www.cantos.com
Cantos.com is an online financial website where top management of companies address the critical issues facing their businesses.
If you would like to contact us, please email enquiries@cantos.com.